Prime Medicine Q4 EPS Beats by 13.4% with $0.22 Loss but Revenue Plummets 63.6%
Prime Medicine reported an adjusted Q4 loss of $0.22 per share, beating the consensus loss estimate of $0.25 and improving from a $0.31 loss a year ago for a 13.4% EPS surprise. Revenue fell 61.5% year-over-year to $0.84 million, missing estimates by 63.6% and marking four consecutive quarters of revenue shortfalls despite a 34.3% YTD stock gain.
1. Q4 Financial Results
Prime Medicine reported an adjusted Q4 loss of $0.22 per share versus a consensus loss estimate of $0.25 and a $0.31 loss in Q4 2024, delivering a +13.39% earnings surprise. The company generated $0.84 million in revenue, down from $2.18 million a year earlier and missing estimates by 63.64%.
2. Recent Trend Analysis
Over the past four quarters, Prime Medicine has surpassed consensus EPS estimates only once and has missed revenue forecasts each quarter, reflecting ongoing commercial challenges. Despite these shortfalls, management’s ability to reduce losses from prior periods indicates progress in cost controls and operational execution.
3. Outlook and Market Reaction
Analysts project a Q1 loss of $0.25 per share on $1.77 million in revenue and a full-year loss of $0.96 per share on $5.31 million in revenue, figures that will shape investor expectations. Shares have climbed 34.3% year-to-date, outperforming the S&P 500, while the Medical-Biomedical and Genetics industry ranks in the bottom 45%, signaling sector headwinds.